← Leaderboards
Sean M Post
University Of Tx Md Anderson Can Ctr
$1,873,784
Attributed
$1,873,784
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $366K · FY2006–20$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$1,873,784 · 2
By mechanism
R01$1,819,019 · 1
F32$54,765 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Michael W Andreeff$17,991,896
- Guillermina Lozano$24,537,407
- Lanlan Shen$6,924,000
- Guojun Li$2,468,355
- Junya Tomida$1,151,217
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorInhibitor/AntagonistPhenotypeGenesProteinsMalignant NeoplasmsMutantPathway InteractionsTp53 GeneTumor Suppressor ProteinsCoupledResponseMutationApoptoticDisease ProgressionCancer CellGene AmplificationBromodomainAnimal ModelDefectDisease RemissionBaseC-Myc GenesAutomobile Driving
Grant awards (7)
Personalized therapy for AML patients with a newly identified genetic alteration$366,000
R01 · FY2020 · CA · contact PI
Personalized therapy for AML patients with a newly identified genetic alteration$355,019
R01 · FY2019 · CA · contact PI
Personalized therapy for AML patients with a newly identified genetic alteration$366,000
R01 · FY2018 · CA · contact PI
Personalized therapy for AML patients with a newly identified genetic alteration$366,000
R01 · FY2017 · CA · contact PI
Personalized therapy for AML patients with a newly identified genetic alteration$366,000
R01 · FY2016 · CA · contact PI
A polymorphism in the Mdm2 promoter enhances cancer risk$4,337
F32 · FY2007 · CA · contact PI
A polymorphism in the Mdm2 promoter enhances cancer risk$50,428
F32 · FY2006 · CA · contact PI